GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
Related
Convenience Shop CEO says direct employment of 200 staff already delivering results
Convenience Shop group has directly employed all its subcontracted staff.
‘It’s in the national interest’: Abigail Agius Mamo calls for action to save Valletta’s traditional shops
She said small shops give towns a unique character and vibrancy that is appealing to tourists.
Hilary Galea-Lauri appointed to EBO.ai’s Board of Directors
The company said that he will provide independent oversight.
Ray Brash named Group Chief Operating Officer at MiFinity
His appointment comes as MiFinity reports continued profitable double-digit revenue growth, expansion into new markets and ongoing investment in new ...
